Evolus, Inc.
EOLS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001570562
In the last 90 days, Evolus, Inc. insiders filed 0 open-market purchases and 1 sale; 158 institutions reported holding it in 13F filings for Q2 2026, worth $384.6M in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $950.0K in total
- 1
- 13F holdersQ2 2026, +12 vs. previous quarter
- 158
- 13F valueReported value at the end of Q2 2026
- $384.6M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding EOLS, Q2 2026
No superinvestor reported holding EOLS at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Evolus, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 4, 2026 (view filing)7:04 PM ET | Sep 2 | 2 days | Moatazedi DavidSee Remarks | SSale | −105.1K | $9.04 | −$950.0K | −17.4%499.6K after | |
| Mar 20, 2026 (view filing) | Mar 20 | Same day | Avelar RuiSee Remarks | SSale | −3.12K | $4.75 | −$14.8K | −0.7%427.4K after | |
| Mar 20, 2026 (view filing) | Mar 20 | Same day | Moatazedi DavidSee Remarks | SSale | −13.7K | $4.75 | −$64.9K | −2.2%604.7K after | 10b5-1 |
| Mar 18, 2026 (view filing) | Mar 17 | 1 day | Moatazedi DavidSee Remarks | SSale | −116.7K | $4.89 | −$570.8K | −15.9%618.4K after | 10b5-1 |
| Mar 18, 2026 (view filing) | Mar 17 | 1 day | Avelar RuiSee Remarks | SSale | −30.0K | $4.89 | −$146.7K | −6.5%430.5K after | 10b5-1 |
| Dec 29, 2025 (view filing) | Dec 22 | 7 days | Moatazedi DavidSee Remarks | SSale | −10.5K | $7.15 | −$75.4K | −2.9%354.4K after | 10b5-1 |
| Dec 29, 2025 (view filing) | Dec 22 | 7 days | Avelar RuiSee Remarks | SSale | −2.26K | $7.15 | −$16.2K | −0.6%356.8K after | 10b5-1 |
| Aug 26, 2025 (view filing) | Aug 22 | 4 days | Yamagishi-Dressler TomokoChief Marketing Officer | SSale | −5.72K | $7.51 | −$43.0K | −6.0%89.9K after | 10b5-1 |
| Aug 18, 2025 (view filing) | Aug 15 | 3 days | Stewart BradyDirector | PPurchase | +30.0K | $6.82 | +$204.6K | +51.2%88.6K after | |
| Jun 16, 2025 (view filing) | Jun 13-16 | 3 days | Moatazedi DavidSee Remarks | SSale | −127.9K | $10.03 | −$1.28M | −26.0%364.9K after | 2 lots |
Top 10 13F holders, Q2 2026
The largest institutional positions in Evolus, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Nantahala Capital Management, LLC | 11,204,042 | $77.8M | 2.36% | +4,827,185+75.7% | Added |
| BlackRock, Inc. | 4,840,828 | $33.6M | 0.00% | +550,445+12.8% | Added |
| Braidwell LP | 3,155,209 | $21.9M | 0.81% | +50,000+1.6% | Added |
| Frazier Life Sciences Management, L.P. | 2,630,665 | $18.3M | 0.40% | 00.0% | Unchanged |
| Perceptive Advisors LLC | 2,459,285 | $17.1M | 0.27% | +1,172,423+91.1% | Added |
| Vanguard Capital Management LLC | 2,362,893 | $16.4M | 0.00% | −107,515−4.4% | Reduced |
| Assenagon Asset Management S.A. | 1,816,360 | $12.6M | 0.01% | +1,218,215+203.7% | Added |
| Millennium Management LLC | 1,787,929 | $12.4M | 0.01% | +326,770+22.4% | Added |
| State Street Corp | 1,697,294 | $11.8M | 0.00% | +376,504+28.5% | Added |
| Geode Capital Management, LLC | 1,608,394 | $11.2M | 0.00% | +227,056+16.4% | Added |